Using generalized linear models with natural-spline smoothing functions, we detected effects of specific xenobiotic metabolizing genes and gene-environment interactions on levels of benzene metabolites in 250 benzene-exposed and 136 control workers in Tianjin, China (for all individuals, the median exposure was 0.512 p.p.m. and the 10th and 90th percentiles were 0.002 and 6.40 p.p.m., respectively). We investigated five urinary metabolites (E,E-muconic acid, S-phenylmercapturic acid, phenol, catechol, and hydroquinone) and nine polymorphisms in seven genes coding for key enzymes in benzene metabolism in humans {cytochrome P450 2E1 [CYP2E1, rs2031920], NAD(P)H: quinone oxidoreductase [NQO1, rs1800566 and rs4986998], microsomal epoxide hydrolase [EPHX1, rs1051740 and rs2234922], glutathione-S-transferases [GSTT1, GSTM1 and GSTP1(rs947894)] and myeloperoxidase [MPO, rs2333227]}. After adjusting for covariates, including sex, age, and smoking status, NQO1*2 (rs1800566) affected all five metabolites, CYP2E1 (rs2031920) affected most metabolites but not catechol, EPHX1 (rs1051740 or rs2234922) affected catechol and S-phenylmercapturic acid, and GSTT1 and GSTM1 affected S-phenylmercapturic acid. Significant interactions were also detected between benzene exposure and all four genes and between smoking status and NQO1*2 and EPHX1 (rs1051740). No significant effects were detected for GSTP1 or MPO. Results generally support prior associations between benzene hematotoxicity and specific gene mutations, confirm earlier evidence that GSTT1 affects production of S-phenylmercapturic acid, and provide additional evidence that genetic polymorphisms in NQO1*2, CYP2E1, and EPHX1 (rs1051740 or rs2234922) affect metabolism of benzene in the human liver.
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Introduction
Benzene is an important industrial chemical that is ubiquitous in the environment owing to vaporization from petroleum products and combustion of hydrocarbons [1] [2] [3] . Occupational exposures to benzene can cause blood disorders, including aplastic anemia, myelodysplastic syndrome, and acute myelogenous leukemia [4] [5] [6] [7] . Significant decreases in the numbers of white blood cells and platelets have been reported in workers exposed to less than one p.p.m. of benzene in air [8] . Although these toxic effects are related to metabolism of benzene in the liver, the particular metabolite(s) that damage bone marrow cells and the mode of toxic action are subjects of debate [9] [10] [11] .
Since the pioneering work of Parke and Williams' [12, 13] , the metabolism of benzene has been extensively investigated (reviewed in [9, 10] ). The major metabolic pathways, shown in Fig. 1 , begin with cytochrome P450 CYP2E1-mediated oxidation of benzene to benzene oxide (BO), which is in equilibrium with its tautomer, oxepin. BO-oxepin is the source of all other major metabolites, namely, phenol (PH), E,E-muconic acid (MA), hydroquinone (HQ), and catechol (CA), and the minor product, S-phenylmercapturic acid (SPMA). All of these metabolites are excreted in urine, either free or in conjugated form. Additional metabolism of the primary metabolites produces additional electrophilic species, including the muconaldehydes (from CYP oxidation of oxepin followed by ring opening), and 1,2-benzoquinone and 1,4-benzoquinone (BQ) (from spontaneous or peroxidase-mediated oxidation of CA and HQ, respectively).
As shown in Fig. 1 , numerous enzyme systems are involved in the metabolism of benzene and its metabolites. In addition to the CYP oxidations of benzene (to BO), oxepin (to the muconaldehydes and ultimately MA) and PH (to HQ) [14] [15] [16] , microsomal epoxide hydrolase (EPHX) catalyzes the hydrolysis of BO to initiate the CA pathway [14, 17] , various glutathione-Stransferases (GSTs) catalyze production of SPMA [18] , and NAD(P)H: quinone oxidoreductase (NQO1) and peroxidases [notably myeloperoxidase (MPO)] are thought to catalyze transformations between CA and HQ and the corresponding quinones (1,2-BQ and 1,4-BQ, respectively) [10, 14, 19, 20] .
It has been speculated that polymorphic genes of the above enzymes predispose some individuals to benzene toxicity through metabolism [21] [22] [23] . In particular, individuals with wild-type MPO (more active) and a variant of NQO1 (less active) were found to be at greater risk of reduced numbers of white blood cells at low levels of benzene exposure [8] . Yet, although GSTT1 polymorphisms have been shown to affect production of the minor metabolite SPMA [24] [25] [26] , there is only sketchy evidence that the major metabolites (PH, MA, HQ, and CA) are affected by polymorphic forms of CYP2E1, EPHX, NQO1, or MPO.
A major difficulty in elucidating the connections between genotypes of metabolizing genes and the corresponding in-vivo phenotypes has been the inability to control for the effects of benzene exposure, and important physiological and lifestyle factors, in observational studies. Indeed, the relationship between metabolite levels and benzene exposure is highly nonlinear and is significantly affected by sex, age, smoking status, and body mass index (BMI) [27, 28] . Using generalized linear models (GLM) with natural spline (NS) smoothing functions, we were able to elucidate the effects of sex, age, smoking status and BMI, after adjustment for benzene exposure (between 0.003 and 88.9 p.p.m.) in a sample of 326 individuals, who were exposed to benzene occupationally and environmentally in Tianjin, China [28] . In the current paper, we extend our application of GLM + NS models to investigate the effects of polymorphic forms of CYP2E1, EPHX, NQO1, MPO, and GSTs on urinary levels of PH, MA, HQ, CA, and SPMA in the same population.
Materials and methods
Study population, and air and biological sample collection Exposed and control study participants were recruited with informed consent from two shoe-making factories and three clothes-manufacturing factories, respectively, in Tianjin, China as described by Lan et al. [8] . Characteristics of the workplaces and levels of benzene exposure have been described previously in detail [8, 27, 29] . After excluding four controls, who were missing measurements of metabolites and/or exposures, the samples included 250 exposed individuals and 136 controls. Exposed and control participants were frequency-matched with respect to sex. Table 1 shows summary statistics for the sex, age and smoking status of participants. Methods of sampling air and urine were also described previously [8, 27, 29] . Briefly, personal full-shift air measurements were matched with urine samples after shift from exposed and control workers. Of the 386 participants in this analysis, 139 had repeated measurements of air and urine, making a total of 617 matched air/ urine samples. Among participants with repeated measurements, the median number of paired air and urine samples was 3 (range 2-4). Information about height, weight, smoking status and other relevant factors were obtained by questionnaire [8] .
This study was approved by the Institutional Review Boards of the University of North Carolina, the University of California, Berkeley, the US National Cancer Institute and the Chinese Academy of Preventive Medicine.
Measurements of air and urinary analytes
Measurements of analytes in air and urine were described previously [27] [28] [29] . Briefly, benzene and toluene were measured in air using passive personal monitors (Organic Vapor Monitors, 3M, St Paul, Minnesota, USA) followed by solvent desorption and gas chromatography [29] . Air measurements of benzene and toluene were below limits of detection [(LOD), nominally 0.2 p.p.m. for benzene and 0.3 p.p.m. for toluene] or were missing for all controls and for some exposed participants (missing values, n = 23; measurements below the LOD, n = 70 for benzene and n = 67 for toluene). Air levels were predicted in these censored and missing air samples from the corresponding urinary levels of benzene and toluene, as described previously for benzene [28] . As summarized in Table 1 , the median air level of benzene was 0.512 p.p.m., the 10th percentile level was 0.002 p.p.m. and the 90th percentile was 6.40 p.p.m. The median air level of toluene was 1.77 p.p.m.
Urinary benzene was determined by gas chromatographymass spectrometry (GC-MS) using head-space solidphase microextraction according to Waidyanatha et al. [30]. Urinary PH, CA, HQ, MA, and SPMA were measured as trimethylsilylether derivatives by GC-MS, after digestion of urine to release conjugates, according to Waidyanatha et al. [31] . Quantification of all urinary analytes was based on peak areas relative to the corresponding isotopically labeled internal standards. The minor metabolite, SPMA, was not detected in 30 urine specimens; a value of LOD= ffiffi ffi 2 p ¼ 0:591nmol=l was imputed to these samples [32] .
Genotyping
We selected nine polymorphisms in seven genes coding for key enzymes in benzene metabolism, on the basis of the evidence of functionality in experimental or human studies (described in the discussion section). As summarized in Table 2 [33] [34] [35] [36] [37] [38] [39] [40] [41] , the following genetic polymorphisms were chosen: CYP2E1 (rs2031920: C-T), two alleles of NQO1 [NQO1*2 (rs1800566: C-T) and NQO1*3 (rs4986998: C-T)], MPO (rs2333227: G-A), GSTM1, GSTT1, and GSTP1 (rs947894: A-G), and two alleles of EPHX1 [(rs1051740: T-C) and (rs2234922: A-G), respectively] [42] . Genotyping was performed with an ABI 7900HT detection system using TaqMan end points as described on the website, http:// snp500cancer.nci.nih.gov [43] . The numbers of participants with each polymorphism of the various metabolizing genes are summarized in Table 2 . Quality control procedures have been described previously [44] . In brief, blind replicate samples were randomly interspersed throughout the study sample plates and showed intrasubject agreement > 99% for all genotype assays.
Statistical analyses
Relationships between levels of the urinary metabolites and the corresponding air concentrations of benzene were examined using GLM + NS models, as described previously [28] . The smoothing functions were based upon 5-knot models for all metabolites, after comparing NS models with 5-7 knots by visual inspection and corrected Akaike's Information Criteria (AICc) [45] . (The candidate knots in the 5-knot model were 0.001, 0.009, 0.512, 1.54, and 11.3 p.p.m. of benzene in air, corresponding to the 5th, 27.5th, 50th, 72.5th, and 95th percentiles [46] , respectively). To avoid overparameterization, nonsignificant knots for each exposure-metabolite relationship were removed by stepwise elimination using a value of P < 0.10 for retention (PROC REG of SAS; SAS Institute, Cary, North Carolina, USA) [28] . For participants with repeated measurements of air and urine, the estimated geometric mean air and metabolite concentrations were used in all statistical analyses.
After establishing NS smoothing functions for each metabolite, we used GLM to investigate effects of genetic polymorphisms and their interactions with benzene exposure and smoking status, after adjusting for the following covariates: sex (0, women; 1, man), age (centered around the estimated mean value of 29.8 years, n = 386), smoking status (0, nonsmoker; 1, smoker), BMI (centered around the estimated mean value of 22.5 kg/m 2 , n = 384). We also investigated effects of toluene exposure (0, low exposure; 1, high exposure; median as a cutoff point, 1.77 p.p.m.) on levels of each metabolite. Potential effects of genetic polymorphisms were screened in two stages to explore exposure-related interactions and smoking-related interactions, respectively. In both stages, the number of effects was restricted to less than 10% of observations to avoid overfitting. Then, important main effects and interactions were pooled from the two stages to build final models. Every candidate model for a given benzene metabolite was sorted by AICc, and the final model was selected from the best and second best candidates, using the following criteria: DAICc, evidence ratio, and the significance and biological plausibility of explanatory variables [45] . Modeling was performed using PROC GLMSELECT of SAS/STAT with the selection/ stop option of AICc [45, 47] .
In coding each genetic polymorphism, the homozygous wild-type was defined as the reference group. For EPHX1 (rs2234922: A-G), variant homozygotes and heterozygotes were combined in the analysis because the former contained only five participants (1.3%) [44] . Tests for Hardy-Weinberg equilibrium (HWE) among participants were conducted on the basis of observed genotype frequencies using PROC ALLELE of SAS/GENETICS (using a Pearson's w 2 test with one degree of freedom). All genotypes were in HWE except MPO (rs2333227: G-A) (P = 0.04). The quality control data were rechecked and the precision of genotyping for this genetic polymorphism in blind replicates was confirmed; so this slight departure from HWE is likely due to chance. Tukey-Cramer adjustment was carried out for multiple comparisons of least-squares means among genetic polymorphisms in the final models.
All statistical analyses were performed using SAS software for Windows ver. 9.13 (SAS Institute).
Results

GLM + NS models and covariate effects
The following NS smoothing functions were used for the five benzene metabolites:
where E[ln(Y m, j )|ln(X j )] is the conditional mean value of ln(Y m, j ) representing the natural log transform of the level of the mth metabolite level in the jth individual exposed at ln(X j ), the corresponding (logged) air concentration of benzene (p.p.m.), and x i is the location of the ith knot (in log-scale of benzene exposure): Genetic
Final GLM + NS models are summarized in Tables 3-7 for the five benzene metabolites. Referring to the nongenetic effects, results are similar to those reported previously without adjustment for genetic polymorphisms [28] . Women participants had higher levels of MA, PH, CA, and HQ than men (P < 0.05) and younger individuals (below 30 years) had higher levels of MA, PH, and HQ than older individuals. Smokers generally had higher levels of benzene metabolites than nonsmokers, but the relationships were complicated by gene-smoking interactions for SPMA, PH, and CA. No significant effects were observed on any of the benzene metabolites for either BMI or coexposure to toluene.
Effects of genetic polymorphisms
After adjusting for exposure and covariates, the following genetic polymorphisms were found to significantly affect levels of the various metabolites, either as main effects or as interactions with benzene exposure and/or smoking: NQO1*2 (rs1800566: C-T) for all metabolites, CYP2E1 (rs2031920: C-T) for all metabolites except CA, GSTT1 and GSTM1 for SPMA, EPHX1 (rs2234922: A-G) for SPMA and CA, and EPHX1 (rs1051740: T-C) for CA. (Note that negative values of estimated parameters indicate lower metabolite levels and vice versa). The interaction between CYP2E1 and benzene exposure accentuated the effects of polymorphic forms of this gene on levels of MA, PH, and HQ among individuals exposed to higher benzene concentrations (Tables 3, 5 and 7). For each of these metabolites, individuals having both variant alleles of CYP2E1 had lower metabolite levels than those with at least one wild-type allele. For example, the relationships for HQ, shown in Fig. 2a , indicate that homozygous variants produced appreciably less metabolite than heterozygotes or homozygous wildtypes at air concentrations greater than 0.1 p.p.m. (Tukey's test, P < 0.05). Similar behaviors were observed for PH, where significant departure was observed above 0.2 p.p.m., and for MA above 2 p.p.m. For SPMA, the effect of CYP2E1 was unclear. Individuals with both variant alleles of CYP2E1 had the lowest metabolite levels at benzene concentrations between 0.02 and 88.9 p.p.m.; however, the difference was not statistically significant (P > 0.05).
Participants with at least one variant allele of NQO1*2 (rs1800566: C-T) had lower levels of all metabolites than homozygous wild-types or heterozygotes (Tables  3-7) . This gene was also found to interact strongly with benzene exposure (for MA, SPMA, and CA) and/or smoking status (for PH and SPMA). These interactions with benzene exposure resulted in participants with at least one variant allele of NQO1*2 (rs1800566: C-T) having lower levels of CA above 0.8 p.p.m. (P < 0.05, Fig. 2b ), lower levels of MA above 6 p.p.m. (P < 0.05), and lower levels of HQ over the entire range of exposure (significance, P < 0.1). Among nonsmokers, participants with NQO1*1/*1 produced more SPMA above 0.5 p.p.m. (Fig. 2c , P < 0.05) and more PH over the entire range of exposure ( Fig. 2d , P < 0.01) than participants with NQO1*2/*2. Among smokers, however, these effects were diminished (Figs. 2d and e) . No effects were observed for NQO1*3 (rs4986998: C-T) polymorphisms.
Strong effects of GSTT1 and GSTM1 were observed on levels of SPMA, with homozygous variants producing the highest levels, followed by heterozygotes and homozygous null individuals (Table 4) . A significant interaction was also observed between benzene exposure and GSTT1 null individuals, such that these workers produced increasingly less SPMA at higher air concentrations (see Fig. 2e ). No effect of polymorphic forms of GSTP1 (rs947894: A-G) was observed on SPMA levels. -G) A Participants with variant alleles of EPHX1 (rs1051740: T-C) had lower levels of CA, particularly among smokers, than homozygous wild-types (see Table 6 ).
Owing to the interaction of EPHX1 (rs1051740: T-C) with benzene exposure, this effect was accentuated among smokers at air concentrations above 0.8 p.p.m.
(P < 0.05) (Fig. 2f) . Participants with at least one variant allele of EPHX1 (rs2234922: A-G) had higher CA levels than homozygous wild-types (P = 0.06). Interestingly, participants with variant EPHX1 (rs2234922: A-G) also had higher levels of SPMA at benzene concentrations above 6 p.p.m. (P < 0.1). No effects were observed for polymorphic forms of MPO (rs2333227: G-A).
Discussion
Although the hematotoxicity of benzene was reported more than a century ago, the mechanism is not yet fully understood [9] . It has been speculated that genetic and lifestyle factors can influence the toxic effects of benzene, but current evidence is far from conclusive [9] [10] [11] . Rothman et al. [23] reported that heavily benzene-exposed workers who were rapid chlorzoxazone metabolizers (a measure of CYP2E1 phenotype) and also possessed variant NQO1*2 (rs1800566: C-T), were at elevated risk of benzene poisoning. More recently, Wan et al. [48] reported increased benzene poisoning in workers with variant NQO1*2 (rs1800566: C-T) and in those with null-type GSTT1 or CYP2E1 DraI, and Lan et al. [8] found lower white blood cell counts in workers with variants of NQO1*3 (rs4986998: C-T) and MPO (rs2333227: G-A). Other studies of polymorphisms among benzene-exposed workers reported that individuals with variant NQO1*2 (rs1800566: C-T) had increased DNA single-strand breaks [49] but decreased aneuploidy [50] in peripheral lymphocytes. The latter study also reported increased aneuploidy in benzeneexposed workers with null deletions of GSTT1 and GSTM1 and with either of two CYP2E1 mutations (DraI or RsaI) [50] .
In the present study, we focused upon the effects of metabolizing genes on production of five prominent metabolites (MA, SPMA, PH, CA and HQ). These metabolites are not 'biological effect markers' [51] per se, but rather reflect primary metabolism in the liver, which appears to be a necessary prelude to benzene-induced toxicity in target organs [9, 10] . Previous attempts to link levels of benzene metabolites with polymorphic forms of metabolizing genes have been hampered by methodological and practical problems, including low benzene exposures (below 0.1 p.p.m.) [18, 25, 26, 52, 53] , no measurements of air exposure [38, 48, 54, 55] , small numbers of participants [25, 26, 50, 53] , and difficulties in adjusting for covariates and nonlinear effects of exposure [24, 49] . As benzene exposures were typically very low in previous studies, only SPMA and MA (metabolites with high specificity for benzene) tended to be measured, and the only consistent effect of any genetic polymorphism was that of lower SPMA levels in individuals with GSTT1 (null deletion) [24] [25] [26] .
We detected several effects of genetic polymorphisms on benzene metabolite patterns and interactions with benzene exposure that have not been reported previously (Tables 3-7) . Our study had substantially more participants (386) and therefore, greater power to detect such effects. Further strengths of our study were the ability to examine effects over a wide range of benzene exposures, determined in both benzene-exposed workers and controls, broad exploration of genetic variants in key genes, evaluation of all major benzene urinary metabolites, and use of GLM + NS models to adjust for exposure and covariates. At the same time, it is possible that some findings could be false positives, and these findings need to be replicated in other large studies.
Individuals with NQO1*2 (rs1800566: C-T) had lower levels of all five metabolites in our study. As NQO1 catalyzes two-election or four-election reductions of quinones [34, [56] [57] [58] [59] , and the NQO1*2 polymorphism is associated with a lack of NQO1*2 protein [20] , it is reasonable that the levels of CA and HQ would be lower in individuals with NQO1*2 (rs1800566: C-T) (Tables 6  and 7 ). When combined with evidence that less active forms of NQO1 are associated with benzene poisoning and DNA damage [8, 23, 48, 49] , this finding is also consistent with speculation that 1,4-BQ and/or 1,2-BQ (the oxidized forms of HQ and CA, respectively) play roles in benzeneinduced toxicity [10, 14, [60] [61] [62] . The fact that levels of the other three metabolites (MA, SPMA, and PH) were also lower among participants with NQO1*2 (rs1800566: C-T), suggests a more general antioxidant role for NQO1 [20] . Furthermore, the interaction effects between NQO1*2 (rs1800566: C-T) and both benzene exposure and smoking status point to induction of NQO1 by reactive benzene metabolites or other reactive species [20, 63, 64] . Such induction could come about via either the antioxidant or xenobiotic response element in the NQO1 promoter region [19, 65, 66] . We found that NQO1*2 (rs1800566: C-T) but not NQO1*3 (rs4986998: C-T) was associated with lower levels of benzene metabolites and that single nucleotide polymorphisms (SNPs) of MPO appeared not to affect metabolism in liver. Considering our previous report of the presence of greater hematotoxicity in workers having the combination of variant NQO1*3 (C/T, less active) and wild-type MPO (A/A, more active) [8] , the present results are interesting. They probably point to differences in the balance between NQO1 and MPO activities in liver (where metabolites are produced) and bone marrow (where metabolites are activated and deactivated in target hematopoietic cells) [60, 67, 68] .
We observed significant effects of CYP2E1 (rs2031920: C-T) variants on levels of MA, PH, and HQ (Tables 3,  5 , and 7). Controversy has surrounded the relationship between the genotype and phenotype of CYP2E1, an important gene that metabolizes many small molecules of toxicological interest, including benzene [21, 22, [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] .
There is some evidence that a variant type CYP2E1 (rs2031920: C-T, also referred to as RsaI -), is associated with decreased CYP2E1 activity in vivo [33, 52, 71, 73, 80, 81] . In the present study, we found that participants with variant CYP2E1 (rs2031920: C-T)
Genetic polymorphisms and benzene metabolism Kim et al. 797 produced lower levels of benzene metabolites at a given benzene exposure than homozygous wild-types, and that the effect was accentuated at higher benzene levels due to gene-environment interactions. The difference in metabolite levels between homozygous wild-types and homozygous variants was detected at benzene exposures in the range of 0.1-2 p.p.m. for HQ, PH and MA (Tables 3, 5 and 7 and Fig. 2a ). This interaction effect could point to induction CYP2E1 (rs2031920: C-T) by benzene exposure, or to more rapid saturation of metabolism among homozygous variant individuals [22] . Therefore, our results substantially support evidence from previous studies [33, 52, 71, 73, 80, 81] that CYP2E1 (rs2031920: C-T) mutations functionally reduce the metabolism of CYP2E1 substrates.
Individuals with variant alleles of EPHX1 (rs1051740: T-C) produced lower levels of CA in our study (Table 6 and Fig. 2f ). EPHX1 enzymes hydrolyze epoxides through the formation of hydroxyl alkyl-enzyme intermediates [82] . Although EPHX1 should logically be involved in benzene metabolism, notably in catalyzing BO to the dihydrodiol, the functional role of this enzyme has been ambiguous in benzene-exposed participants [56, 83] . Two polymorphisms have been identified; one, in exon 3, decreased enzymatic activity 50% in vitro, whereas the other, in exon 4, increased activity 25% [84] . Our findings that workers with variant allele(s) of EPHX1 (rs1051740: T-C) had lower levels of CA than homozygous wildtypes, whereas those with at least one variant of EPHX1 (rs2234922: A-G) had marginally higher CA levels, support the in-vitro results. We also detected significant interactions between EPHX1 (rs1051740: T-C) and both benzene exposure and smoking status. The genesmoking interaction tended to accentuate differences in CA levels between smoking individuals who had different alleles of EPHX1 (rs1051740: T-C) and to obscure effects among nonsmokers (Fig. 2f) . The gene-exposure interaction produced differences in CA levels that could be distinguished between smokers having homozygous wild-types and variant-types of EPHX1 (rs1051740: T-C) at benzene concentrations above 1 p.p.m. Our results are intriguing in light of recent epidemiologic studies indicating that, among smokers, fast EPHX1 metabolizers had greater risks of colorectal adenomas [85, 86] than slow metabolizers. Interestingly, fast metabolizers of EPHX1 (rs2234922: A-G) also had marginally higher levels of SPMA at benzene concentrations above 6 p.p.m. (P < 0.10). Although the mechanism for production of SPMA is not yet established [87, 88] , the apparent effect of EPHX1 on SPMA levels may offer clues regarding formation of this minor benzene metabolite [82] .
Among the GST isozymes, both GSTM1 and GSTT1 affected the production of SPMA (Table 4 , Fig. 2e) , with individuals having variant forms of these enzymes producing lower levels. Of the two isozymes, GSTT1 produced more substantial effects, based upon evidence ratios [45] (data not shown), and produced different profiles for each combination of alleles (Fig. 2e) . This finding is consistent with previous studies [24] [25] [26] . No effect of GSTP1 (rs947894: A-G) was detected.
Finally, it is worth commenting upon the amounts of variability in metabolite levels that were explained by the observed genetic effects and the magnitudes of interindividual differences in metabolism that can be attributed to particular genes. The GLM + NS models summarized in Tables 3-7 had R 2 (%) values of 85.0 for MA, 82.0 for SPMA, 64.8 for PH, 57.2 for CA, and 72.6 for HQ, among which benzene exposure and nongenetic covariates explained between 53 and 84% of the variability in metabolite levels. The corresponding percentages of variability explained collectively by all significant genes and gene-environment interactions were 1.0 for MA, 4.9 for SPMA, 3.1 for PH, 3.4 for CA, and 1.8 for HQ. Thus, although many significant genetic effects were detected, they collectively contributed rather little to the explained variation in benzene metabolism.
Regarding interindividual differences in metabolism that would be expected for a given genetic polymorphism, Table 8 lists the ratios of predicted metabolite levels for homozygote variants to homozygous wild-types, based upon least-squares means of the models summarized in Tables 3-7 . These ratios represent the mean fold ranges for variant/referent that would be expected for each genetic polymorphism after adjusting for benzene exposure as well as covariates and other genetic effects. The values shown in Table 8 suggest that interindividual differences in metabolite production were generally rather modest, with most ratios lying between about 0.3 and 2.0. Indeed, differences as great as two-fold to 3.5-fold would only be anticipated for most metabolite-gene combinations when persons were exposed to very high benzene concentrations (100 p.p.m.). The exception to this rule is the large effect of GSTT1 on SPMA production, where homozygous referents would typically have SPMA levels three-fold to eight-fold greater than those of homozygous variants. This large fold range undoubtedly contributed to the earlier reports of significant effects of GSTT1 on SPMA levels [24] [25] [26] .
In conclusion, we used GLM + NS regression to detect numerous effects of particular metabolizing genes and gene-environment interactions on levels of benzene metabolites in 386 Chinese workers. Of the nine genetic polymorphisms investigated, NQO1*2 (rs1800566: C-T) affected all five metabolites, CYP2E1 (rs2031920: C-T) affected all metabolites but CA, EPHX1 (1051740: T-C or 2234922: A-G) affected CA and SPMA, and GSTT1 and GSTM1 affected SPMA. Significant interactions were detected between benzene exposure and all four genes [including CYP2E1 (rs2031920: C-T), NQO1*2 
